184 related articles for article (PubMed ID: 35092403)
1. Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma.
Eskander NS; Mansour L; Abdelaal A; Saad E; Mohamed D
Asian Pac J Cancer Prev; 2022 Jan; 23(1):339-348. PubMed ID: 35092403
[TBL] [Abstract][Full Text] [Related]
2. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
3. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
[TBL] [Abstract][Full Text] [Related]
4. CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
Sefrioui D; Beaussire L; Gillibert A; Blanchard F; Toure E; Bazille C; Perdrix A; Ziegler F; Gangloff A; Hassine M; Elie C; Bignon AL; Parzy A; Gomez P; Thill C; Clatot F; Sabourin JC; Frebourg T; Benichou J; Bouhier-Leporrier K; Gallais MP; Sarafan-Vasseur N; Michel P; Di Fiore F
Br J Cancer; 2021 Aug; 125(5):725-733. PubMed ID: 34112948
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
6. Investigation of Efficacy Evaluation Comparison of cfDNA and CEA in Colorectal Cancer.
Yu D; An G; Xu L
Clin Lab; 2016 Oct; 62(10):1947-1953. PubMed ID: 28164530
[TBL] [Abstract][Full Text] [Related]
7. Cell-free DNA as a biomarker for colorectal cancer: a retrospective analysis in patients before and after surgery.
Zhong Y; Zhou Q; Zhang Y; Zhou S; Zhang G; Jiang C; Zhang Z; Zhang X; Xu J; Jin C; Cao L; Chen L
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):135-141. PubMed ID: 32415940
[TBL] [Abstract][Full Text] [Related]
8. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
9. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
10. Serum cell-free DNA concentrations and integrity analysis of colorectal cancer patients before and after surgery.
Cao G; Xie Y; Jiang X; Tian X; Wang D; Sun Y
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):44-51. PubMed ID: 31472046
[TBL] [Abstract][Full Text] [Related]
11. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
12. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
13. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
14. Increased Free Circulating DNA Integrity Index as a Serum Biomarker in Patients with Colorectal Carcinoma.
El-Gayar D; El-Abd N; Hassan N; Ali R
Asian Pac J Cancer Prev; 2016; 17(3):939-44. PubMed ID: 27039817
[TBL] [Abstract][Full Text] [Related]
15. Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy.
Manojlovic N; Savic G; Nikolic B; Rancic N
World J Clin Cases; 2022 Jan; 10(3):899-918. PubMed ID: 35127905
[TBL] [Abstract][Full Text] [Related]
16. Combining
Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
[TBL] [Abstract][Full Text] [Related]
17. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
Barault L; Amatu A; Siravegna G; Ponzetti A; Moran S; Cassingena A; Mussolin B; Falcomatà C; Binder AM; Cristiano C; Oddo D; Guarrera S; Cancelliere C; Bustreo S; Bencardino K; Maden S; Vanzati A; Zavattari P; Matullo G; Truini M; Grady WM; Racca P; Michels KB; Siena S; Esteller M; Bardelli A; Sartore-Bianchi A; Di Nicolantonio F
Gut; 2018 Nov; 67(11):1995-2005. PubMed ID: 28982739
[TBL] [Abstract][Full Text] [Related]
18. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery.
Zhang X; Wu Z; Shen Q; Li R; Jiang X; Wu J; Li D; Wang D; Zou C; Zhong Y; Cheng X
Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):111-117. PubMed ID: 31880527
[TBL] [Abstract][Full Text] [Related]
20. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
Jia J; Zhang P; Gou M; Yang F; Qian N; Dai G
Dis Markers; 2019; 2019():6812045. PubMed ID: 30805037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
